Condition category
Surgery
Date applied
02/12/2013
Date assigned
27/01/2014
Last edited
10/04/2015
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
An endovascular aneurysm is a bulge in a blood vessel that is caused by a weakness in the blood vessel wall, usually where it branches. Percutaneous access (access to inner organs via needle-puncture of the skin) for endovascular aneurysm repair (called P-EVAR) using a suture-mediated closure device was first described in 1999. P-EVAR has gained great interest as it may reduce surgery time and decrease time to recovery. However, suture-mediated closure devices increase the procedural cost. The fascia suture technique (FST) was described in 1997 and was first evaluated by our group in 2006. The aim of this study was to investigate whether FST reduces the time and cost of the procedure in comparison to pre-suturing using the Prostar XL percutaneous Vascular Surgical system.

Who can participate?
Patients planned for abdominal endovascular aortic repair (EVAR) or thoracic endovascular aortic repair (TEVAR) for aneurysm or dissection.

What does the study involve?
Participants are randomly allocated to one of two groups:
1. Intervention group: patients will have a fascia suture for access closure
2. Control group: patients will have the Prostar access closure

What are the possible benefits and risks of participating?
The two methods to be compared have been used for several years in routine treatment. These methods have shown a high success rate and severe complications have been rare. Patients are not expected to be at greater risk than if they had not been involved in the study. Improved care through more systematic monitoring was considered as one of the potential benefits for the patients.

Where is the study run from?
The study is run from Örebro University Hospital and Sahlgrenska University Hospital, Göteborg, Sweden.

When is the study starting and how long is it expected to run for?
The recruitment started in June 2006 and the last patient was enrolled in May 2009. The last follow-up took place in December 2009.

Who is funding the study?
Örebro University Hospital, Sweden.

Who is the main contact?
Dr Thomas Larzon
thomas.larzon@orebroll.se

Trial website

Contact information

Type

Scientific

Primary contact

Dr Thomas Larzon

ORCID ID

Contact details

Department of Cardiothoracic and Vascular Surgery
Örebro University Hospital
Örebro
SE-70185
Sweden
+46 (0)19 602 10 00
thomas.larzon@orebroll.se

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

N/A

Study information

Scientific title

Randomized two-centre trial to investigate whether the fascia suture technique (FST) can reduce access closure time and procedural costs in comparison to the Prostar technique (Prostar) in patients undergoing endovascular aortic repair and to evaluate the short- and mid-term outcome of both techniques

Acronym

Study hypothesis

It was hypothesised that that the fascia suture technique could reduce access closure time and procedural costs in comparison to the Prostar technique in patients undergoing endovascular aortic repair.

Ethics approval

Regional Ethical Review Board, regional ethical committee, Uppsala, 07/09/2005, ref.:Dnr 2005:144

Study design

Randomised two-centre trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Improving surgical performance

Intervention

Participants are randomised to one of the following two groups:
1. Intervention group: patients having a fascia suture for access closure
2. Control group: patients having the Prostar access closure

Intervention type

Procedure/Surgery

Phase

Drug names

Primary outcome measures

Current primary outcome measures as of 18/06/2014:
Time for access closure, measured with a stopwatch during the primary procedure

Previous primary outcome measures:
1. Time for access closure, measured with a stopwatch during the primary procedure
2. Cost for access closure, measured at the primary procedure and at reported adverse event leading to an additional procedure and/or hospital stay during the 6-month follow-up period by calculation of material cost (disposables), cost for operative procedure (minutes), ICU stay (hours) and hospital stay (days)

Secondary outcome measures

Current secondary outcome measures as of 18/06/2014:
Previous secondary outcome measures:
1. Technical success of access closure
2. Access-related complications
3. Cost for access closure, measured at the primary procedure and at reported adverse event leading to an additional procedure and/or hospital stay during the 6-month follow-up period by calculation of material cost (disposables), cost for operative procedure (minutes), ICU stay (hours) and hospital stay (days)

Both outcomes will be measured at the operative procedure, at discharge, at 30 days and 6 months follow-up by doctor´s preference and ultrasound at 1 and 6 months.

Previous secondary outcome measures:
1. Technical success of access closure
2. Access-related complications

Both outcomes will be measured at the operative procedure, at discharge, at 30 days and 6 months follow-up by doctor´s preference and ultrasound at 1 and 6 months.

Overall trial start date

07/06/2006

Overall trial end date

10/12/2009

Reason abandoned

Eligibility

Participant inclusion criteria

1. All patients planned for abdominal endovascular aortic repair (EVAR) or thoracic endovascular aortic repair (TEVAR) for aneurysm or dissection
2. Planned femoral access
3. Planned for at least 16 F outer diameter of introducer or stent graft system on the main access site

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

100

Participant exclusion criteria

1. Aorto-uni-iliac stentgrafts with femoro-femoral bypass
2. Femoral aneurysm
3. Ruptured aneurysms
4. Emergency operations without preoperative ultrasound
5. Ongoing anticoagulation treatment with warfarin

Recruitment start date

07/06/2006

Recruitment end date

01/05/2009

Locations

Countries of recruitment

Sweden

Trial participating centre

Örebro University Hospital
Örebro
SE-70185
Sweden

Sponsor information

Organisation

Örebro University Hospital (Sweden)

Sponsor details

Department of Cardiothoracic and Vascular Surgery
Örebro
SE-70185
Sweden
+46 (0)19 602 10 00
chatarina.lindahl@orebroll.se

Sponsor type

Hospital/treatment centre

Website

http://www.orebroll.se

Funders

Funder type

Hospital/treatment centre

Funder name

Örebro University Hospital (Sweden)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/25549577

Publication citations

Additional files

Editorial Notes